drugset / Trial / NCT01823510
Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients
RandomizedCrossoverSingle-blindTreatment
Summary
The purpose of this study is to determine whether treatment with ticagrelor + aspirin is more effective than treatment with clopidogrel + aspirin in patients with type-2 diabetes. Both treatments will be given (separately) to all subjects as a one-time loading dose (i.e. higher than a normal daily dose), followed by daily dose for the next 5 to 7 days. Effectiveness of treatment will be measured with specialized blood tests before the loading dose, at two time-points after the loading dose, and once after the last daily dose.
Timeline
- Start
- 2013-07
- Primary completion
- 2016-05-10
- Completion
- 2016-05-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clopidogrel | Small molecule | 75 mg | — |
| Subject | Ticagrelor | Small molecule | 90 mg | — |
| Background | Aspirin | Small molecule | 81 mg | — |